The effect of Nintedanib in post-COVID-19 lung fibrosis: an observational study

• Conditions: Patients with COVID-19 pneumonia and lung fibrosis; COVID-19; Pneumonia; Lung fibrosis; Nintedanib; Antifibrotic; Oxygenation; Chest radiograph; Mortality

• Registration Number: TCTR20220426001
• Lead Sponsor: Faculty of Medicine, Thammasat University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-04-26
• Study Completion: 2022-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

1. Age 18 years or more, 2. Diagnosis of COVID-19 confirmed by RT-PCR test for SAR-CoV-2, 3. Diagnosis of pneumonia confirmed by chest imaging, 4. Hospital admission at Thammasat University Hospital, 5. Treatment with nintedanib or standard treatment

Exclusion Criteria

None

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Oxygenation improvement at 60 days after treatment Number (%),Chest X-ray improvement at 60 days after treatment Number (%),Mortality rate at 60 days after treatment Number (%)

Secondary Outcome Measures

Name	Time	Method
ength of hospital stay at the end of study days,SpO2/FiO2 ratio difference between before and after treatment at the end of study number